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1. Introduction 
Positron emission tomography (PET) is a three-dimensional nuclear medicine imaging 
technique that provides metabolic information about the body. This technique was first 
introduced by Kuhl et al. (Kuhl, Chamberlain et al. 1956). The basic principle of this system 
is to detect pairs of gamma rays emitted indirectly by a positron-emitting radionuclide 
(tracer), which is introduced into the body on a biologically active molecule. The metabolic 
information as three-dimensional imaging is obtained from the positional information of the 
tracer, obtained by computer analysis of the gamma rays. The metabolic information 
obtained is considered a functional imaging technique, whereas computed tomography (CT) 
and magnetic resonance imaging (MRI) are regarded as morphologic imaging techniques. 
Moreover, the fusion of PET with CT (PET-CT) has further elevated the precision of 
functional imaging techniques. Clinical applications of PET have increased in the last decade 
and have proven to be vital in the evaluation and diagnosis of diseases. The broad scope, 
versatility and sensitivity of PET make it the most powerful molecular imaging technique 
currently available for clinical use. 
2. Clinical use of PET 
PET is currently employed for preliminary diagnosis, evaluation of therapy and to 
determine the aggressiveness of a disease. Its most common and beneficial use is in 
oncology. The therapeutic strategy used in oncology must be developed according to the 
stage of the malignancy. The importance of staging derives from the clinical finding that the 
prognosis of patients with localized malignant disease is generally much better than those 
with metastases throughout the body. PET is also used for assessment of a viable 
myocardium that may respond to reperfusion and for medically refractory epilepsy.  
The measurement of glucose metabolic rate is one of the prime measures of physiology in 
the human body. Anaerobic glycolysis is an early indicator of malignant transformation of 
cells (Schlyer 2004). Whole-body PET imaging with 18F-fluoro-2’-deoxy-D-glucose (18FDG), 
enables the evaluation of glucose metabolism throughout the entire body in a single 
examination to improve the detection and staging of a cancer, selection of therapy, and 
assessment of therapeutic response. Clinical indications for 18FDG-PET imaging are well 
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documented for many solid tumors in adults. Several studies have established that 18FDG-
PET techniques have higher specificity than CT (Czernin 2002).  
This article focuses on the clinical use of PET in spine surgery. First, we describe the 
feasibility of using PET for obtaining a preliminary diagnosis, including peripheral benign 
nerve tumors. Second, the use of PET to assess the functional impairment of the spinal cord 
in patients with cervical myelopathy is described. 
3. Feasibility of the use of PET for preliminary diagnosis 
In clinical situations, spine surgeons often encounter patients demonstrating intractable pain 
or progressive neurologic deficits of unknown origin that cannot be detected by 
conventional imaging tools. We have had two cases for which PET provided helpful 
evidence in obtaining a definitive diagnosis.  
3.1 Case report (intractable pain) 
A 37-year old woman experienced severe sciatica after hitting her left buttock with great 
force on the edge of a bathtub. A physical examination demonstrated intense radiating pain 
from the left buttock to the lateral calf. There was weakness in the sciatic nerve innervated 
musculature. She was diagnosed with Piriformis syndrome by a local hospital. However, 
her symptoms remained unchanged after surgery to release the Piriformis. Conventional 
imaging of the sciatica, including plain radiographs, CT and MRI of the spine, showed no 
abnormal findings. 18FDG-PET detected an abnormal lesion in the sciatic nerve in the 
posterior compartment of the patient’s left thigh, indicating an intraneural tumor in the 
sciatic nerve. Subtotal resection was achieved and the histological evaluation of the 
specimen showed typical features of nodular fasciitis (Figure 1). After surgery, the patient 
was relieved of all symptoms with no evidence of recurrence at a recent two-year follow-up 
(Kakutani, Doita et al.). 
3.2 Case report (Wegener’s granulomatosis) 
A 61-year old woman presented with progressive back pain, low-grade fever and gait 
disturbance. She was admitted to our hospital with paralysis of the left lower limb and 
bladder and rectal disturbances. A neurological examination revealed hyper-reflexia of the 
left patella and Achilles tendons, a positive Babinski’s reflex, muscle weakness in the left 
lower extremities, foot drop and hypoesthesia below the T3 dermatome. The cranial nerve 
was not impaired. MRI of the thoracic spine revealed a diffuse space-occupying lesion at the 
anterior spinal cord in Th2-7. The lesion was hypointense on T1–weighted images and 
hyperintese on T2–weighted images. The lesion was enhanced after administration of 
contrast medium. 18FDG-PET detected high uptake in the thoracic spine, bilateral upper 
lungs, and surrounding tissue of the abdominal aorta (Figure 2). Despite hospital admission 
and bed rest, the neurological deficit deteriorated, and the authors performed a 
laminectomy at Th1-T6 and posterior fusion with instrumentation at C7-Th7, including open 
biopsy. The histological examination of the surgical specimen showed fibrin deposition and 
granulation tissue formation with inflammatory infiltrate; no definitive diagnosis could be 
obtained from the surgery and biopsy. However, in addition to the abnormal 18FDG-PET 
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findings, further examinations revealed elevated levels of MPO-ANCA of 66 U/ml 
(normal<10.0 U/ml) and we concluded that the epidural spinal tumor was a complication 
associated with Wegener’s granulomatosis. The high uptake in the bilateral upper lungs and 
surrounding tissue of the abdominal aorta detected by 18FDG-PET was the conclusive 
evidence for the definitive diagnosis of Wegener’s granulomatosis (Kasagi, Saegusa et al.).  
 
 
Fig. 1. Nodular fasciitis in the sciatic nerve detected by 18FDG-PET (a,b). T2-weighted MRI 
(c) and Gd enhanced MRI (d) demonstrated the mass in the right hamstring. After fascicular 
dissection, the lesion under fascicular of sciatic nerve is disclosed entrapping the 
perineurium of sciatic nerve(e). 
 
Fig. 2. MRI showing a diffuse space-occupying lesion at the anterior spinal cord: T2-
weighted MRI (a); Gd-enhanced (b). Axial CT (c,e); axial PET/CT fusion (d,f) and sagittal 
PET image (g) demonstrating FDG uptake in the abdominal aorta and bilateral upper lungs.  
a b e
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Although these two case reports represent very rare cases, 18FDG-PET provided helpful 
diagnostic clues for obtaining the definitive diagnosis. While meticulous physical 
examinations and the symptoms themselves are usually enough to aid identification of the 
correct pathomechanism, spine surgeons often encounter patients whose cases are difficult 
to diagnose using conventional imaging tools, such as MRI and CT. In our cases, the 
differential diagnosis was intramedullary tumor, extraspinal neurogenic tumor, especially in 
the pelvis, or inflammatory lesion of the central nervous system (CNS), including the 
neurosarcoidosis and human T-lymphotropic virus type I-associated myelopathy (HTLV-1 
myelopathy). Conventional imaging tools, MRI, CT and scintigraphy, revealed pathological 
changes consistent with these diagnoses; however MRI without enhancement with 
gadolinium did not indicate the abnormal findings expected in intramedullary tumor or 
inflammatory lesion of the CNS. Furthermore, almost all neurogenic tumors are negative 
with tumor scintigraphy by 67Ga-citrate, 201TICI and Tc-99m. In contrast, PET, providing 
metabolic information as three-dimensional imaging, can reveal neurogenic tumors in the 
whole body and CNS inflammatory lesions (Zhuang, Yu et al. 2005). FDG-PET is not only 
important for detecting malignant tumors, but also has potential for evaluation of a variety 
of inflammatory and infectious disorders (Zhuang, Yu et al. 2005). Because 18FDG, the most 
common radiopharmaceutical for PET in oncology, is not tumor-specific, 18FDG-PET cannot 
differentiate between malignancies and inflammatory processes, a disadvantage for 
oncological diagnoses. This property is, however, an advantage for screening spinal and 
neurogenic disorders. 
3.3 Tumors and inflammation 
Significant tracer accumulation can also occur in viral, bacterial and fungal infections, or in 
other forms of inflammatory tissue. FDG accumulation in inflammatory tissue may cause 
false positives during cancer screening. Other PET tracers considered to be proliferation 
markers may allow improved differential diagnosis of tumor and inflammation. 
Proliferation activity can be measured by lipid precursors, amino acids, nucleosides and 
receptor ligands. Only labeled nucleosides incorporated into DNA are true proliferation 
markers, while amino acid transport, membrane metabolism, enzyme activity and receptor 
expression can serve as surrogate markers of cellular proliferation based on the tissue 
kinetics. Established imaging targets for oncology are: (i) glucose transport (18FDG); (ii) 
choline kinase activity (11choline); (iii) amino acid transport (11C-methionine); and (iv) 
activity of thymidine kinase 1 (18FLT). Radiolabeled choline, amino acids and nucleosides 
have been reported to show greater tumor-specificity than 18FDG, both in experimental 
animals and in humans (van Waarde and Elsinga 2008), although the specificity of any 
tracer is not absolute. FDG, choline and C-methionine are accumulated in such 
inflammatory process as bacterial and sterile infections. Although proliferation activity is a 
key factor of malignancy, cell division can also occur in benign tumors and inflammation 
processes. Consequently the tumor specificity of PET will never achieve 100%. 
Sahlmann et al. reported that the dual time point 18FDG uptake, which was measured at 30 
and 90 minutes after injection, showed different pattern between chronic bacterial 
osteomyelitis and malignant bone tumor. In osteomyelitis, the standard uptake value (SUV) 
between 30 and 90 minutes post-injection remained stable or decreased, while, in contrast, in 
malignant bone tumor, the SUV between 30 and 90 minutes post-injection increased 
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(Sahlmann, Siefker et al. 2004). Moreover, high-grade sarcomas were found to reach peak 
activity concentration approximately 4 hours after injection of FDG, while benign tumors 
reached maximum within 30 minutes (Lodge, Lucas et al. 1999). Thus, the dynamic dual 
time point 18FDG-PET provides is a characteristic pattern in chronic osteomyelitis, similar to 
inflammatory processes in other locations, differentiating it from malignant tumors. 
However, clarification of the difference between inflammatory lesions and benign tumors, 
which have similar uptake patterns, is yet to be accomplished.  
3.4 Benign and malignant neurogenic tumors 
The cause of nerve pain and neurological deficit is often considered to be extradural tumors, 
including such neurogenic tumors as schwannoma, neurofibroma, perineurioma, 
intraneural ganglion and malignant peripheral nerve sheath tumor (MPNST), as well as 
such intradural tumors as schwannoma, meningioma and ependynoma, etc (Figure 3,4). 
Generally detection of these benign neurogenic tumors by tumor scintigraphy using 67Ga-




Fig. 3. CT, FDG and PET/CT images showing accidental detection of schwannoma in the 
left brachial plexus.  
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Fig. 4. Malignant peripheral nerve sheath tumor (MPNST) located in the right brachial 
plexus and the left upper lung demonstrated by axial CT (a), axial PET (b), axial PET/CT 
fusion (c) and coronal PET (d).  
In contrast, 18FDG-PET reveals benign neurogenic tumors and menigiomas in the whole 
body (Ahmed, Watanabe et al. 2001);(Lippitz, Cremerius et al. 1996; Antoch, Egelhof et al. 
2002; Beaulieu, Rubin et al. 2004; Ghodsian, Obrzut et al. 2005; Hamada, Ueda et al. 2005; 
Halac, Cnaral et al. 2008). Studies have investigated the tumor growth characteristics of 
schwannoma and meningioma by PET. Ahmed et al. retrospectively reviewed schwannoma 
of the extremities in 22 patients. They found that 18FDG-PET and 18FMT-PET, in which 18F-
fluoro-α-methyl tyrosine (18FMT) is an amino acid tracer to monitor protein metabolism, 
detected schwannoma in all cases, and reflected proliferation activity of the schwannoma. 
The authors suggested that 18FMT-PET is more reliable for differentiation between benign 
schwannoma and malignancy than 18FDG-PET (Ahmed, Watanabe et al. 2001). Kubota et al. 
studied the feasibility of differentiating benign and malignant schwannomas by dual time 
point 18FDG-PET, comparing uptake 1 hour post-injection to 2 hours post-injection. Most 
malignant schwannomas showed greater increase at 2 hours post-injection than at 1 hour 
post–injection, while most normal tissue showed lower 18FDG uptake at 1 hour than at 2 
hours (Kubota, Itoh et al. 2001). In addition, from analysis of the SUV of 18FDG on 55 
patients with benign and malignant tumors involving the musculoskeletal system, the cut-
off point, 1.9, was calculated and the sensitivity of 18FDG -PET for correctly diagnosing 
malignancy was 100%, with a specificity of 76.9% and an overall accuracy of 
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SUV can furnish useful diagnostic information for differentiating benign and malignant 
schwannomas. 
In contrast, because meningioma cells have high uptake levels for 1,4,7,10-
tetraazacyclododecane-N,N',N",N"'-tetraacetic-acid-D-Phe1-Tyr3-oc treotide (68Ga-
DUTATOC), a new PET radiotracer with high specific binding to somatostatin receptors, 
68Ga-DUTATOC can be used to image the meningioma (Henze, Schuhmacher et al. 2001). 
Lipptiz et al. investigated the correlation of 18FDG-uptake with the histopathology, 
cellularity and proliferation rate of intrancanial meningioma. They found significant 
differences between 18FDG-uptake in World Health Organization (WHO) grade I vs. grades 
II and III, low vs. high cellularity and Ki-67 index < 2% vs. > 2% intracranial meningomas 
(Lippitz, Cremerius et al. 1996). These results indicate that a portion of a tumor can be 
imaged using this specific tracer and dynamic dual time point examination and show that 
PET is useful not only for screening but also as a noninvasive predictor of tumor growth 
characteristics of schwannoma and meningioma.  
3.5 Inflammatory lesion of spinal cord 
When clinical manifestations are more severe than imaging indicates an inflammatory lesion 
of the spinal cord should be considered in the differential diagnosis. Inflammatory diseases of 
the spinal cord, such as neurosarcoidosis and HTLV-1 myelopathy, present a wide spectrum of 
clinical and radiological manifestations, making them difficult to diagnose. Bolat et al. 
explored the usefulness of PET in the diagnosis of neurosarcoidosis (Bolat, Berding et al. 2009). 
In addition, Umehara et al. found 18FDG-PET to be helpful for diagnosing HTLV-1 
myelopathy (Umehara, Hagiwara et al. 2008). Radu et al. measured experimental autoimmune 
encephalomyelitis by 18FDG-PET; their results highlighted the potential use of serial 18FDG-
PET for monitoring neuroinflammation in encephalomyelitis. They also suggested that similar 
approaches could be applied to the diagnosis and evaluation of other autoimmune and 
inflammatory disorders in animal models and humans (Radu, Shu et al. 2007).  
4. Prediction of surgical outcomes in cervical sclerotic myelopathy 
Conventional morphological imaging with CT and MRI can visualize precisely the location 
and pathological cause of stenosis and compression; however the severity of morphological 
stenosis does not necessarily correlate with either the actual functional deficits or the clinical 
course of the condition. Therefore, alternative diagnostic methods to morphological imaging 
are needed to better reflect the functional impairment of the cervical cord. 
To accurately predict prognosis and neurological improvement after neurosurgical 
decompression, it is essential to be able to assess spinal cord function in patients with 
cervical compression myelopathy. Most conventional evaluations focus on morphologic and 
pathologic changes to the compressed cord, which can be identified on MRI. MRI is a 
valuable tool because it visualizes not only the magnitude of the spinal cord compression, 
but also intramedullary signal intensity. Several investigators have reported a correlation 
between morphologic and pathologic changes on MRI and neurologic status, with most 
studies suggesting that preoperative MRI findings could be used to predict surgical 
outcome and prognosis (Okada, Ikata et al. 1993; Wada, Yonenobu et al. 1999; Singh, 
Crockard et al. 2001; Alafifi, Kern et al. 2007).  
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The spinal cord is considered to have viscoelastic properties that allow it to return to its 
original configuration following decompression, leading to recovery of physiologic function 
of sensorimotor pathways. However, spinal cord atrophy is associated with significantly 
reduced extensibility and the atrophic spinal cord in patients with profound paresis fails to 
regain its original configuration after decompression. It has been reported that patients who 
show early postoperative expansion of the spinal cord tend to have favorable neurologic 
improvements (Baba, Maezawa et al. 1997). The restoration of the transverse area and 
sagittal diameter of the spinal cord also correlates with better neurologic improvement 
(Fukushima, Ikata et al. 1991; Yone, Sakou et al. 1992). An important issue is the significance 
of changes in MRI intramedullary signal intensity. Increased capillary permeability with 
subsequent stromal edema and venous congestion can be visualized on T2-weighted MRI. 
Although it is unclear whether intramedullary signal intensity of the spinal cord on a T2-
weighted MRI can be used to predict neurologic recovery following decompression, a 
number of investigators have suggested that high-signal intensity on T2-weighted MRI is a 
marker for poor neurologic prognosis (Ramanauskas, Wilner et al. 1989; Mehalic, Pezzuti et 
al. 1990); (Takahashi, Yamashita et al. 1989).  
The central nerve system, brain and spinal cord, is known to mainly utilize glucose for basic 
metabolism. 18FDG-PET can reflect spinal cord neural cell activity by visualization and 
measurement of glucose utilization. In myelopathy patients, 18FDG-PET uptake and glucose 
utilization rate in the cervical spinal cord is variable. Metabolic evaluation of space-
occupying and spinal cord-compressing spinal cord abnormalities with 18FDG-PET has been 
used successfully for more than 25 years, especially for neoplastic disease (Nguyen, Sayed et 
al. 2008) (Francken, Hong et al. 2005); (Di Chiro, Oldfield et al. 1983; Meltzer, Townsend et 
al. 1998; Wilmshurst, Barrington et al. 2000; Poggi, Patronas et al. 2001). In all these space-
occupying and spinal cord-compressing lesions, 18FDG-PET was used to differentiate 
between benign and malignant abnormalities or to monitor the biological activity of a 
condition. Consequently, 18FDG-PET should be considered a contemporary advanced 
technology for further assessment of chronically damaged spinal cords in patients with 
cervical myelopathy.  
SUV is a potentially suitable parameter for assessment of neurologic status in clinical 
practice. Kamoto et al. reported that the normal value of metabolic rate of glucose utilization 
in the cervical spinal cord in healthy Japanese subjects was 1.93 ± 0.23 (Kamoto, Sadato et al. 
1998). Although several investigators have reported 18FDG uptake levels in cervical 
compressive myelopathy, the relationship between metabolic activity and severity of 
neurologic dysfunction is controversial.  
Baba et al. utilized mouse animal models and observed that during the early stages of cord 
compression, neuropeptide activity in neurons and glial cells was increased by external 
pressure, thus stimulating glucose utilization by the spinal cord. Chronic compression, 
however, leads to atrophy and necrosis of anterior grey horn cells, and the loss of glucose-
consuming neurons leads to decreased 18FDG uptake of the spinal cord (Baba, Uchida et al. 
1999). Uchida et al. reported that patients with mild to moderate myelopathy have a 
significantly higher SUV, while those with marked and profound tetraparaesis have 
significantly lower values (Uchida, Kobayashi et al. 2004). Uchida et al. also analyzed the 
SUV during neurologic improvement of cervical myelopathy, and found that more 
improved patients had significantly higher preoperative SUV compared to patients with less 
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improvement (Uchida, Nakajima et al. 2009). Interestingly, classification by preoperative 
SUV did not differ significantly from classification by the intramedullary signal intensity of 
the spinal cord on MRI. It is possible that the absolute level of the SUV is not decisive for 
assessment of the metabolic status of the cervical cord. Floeth et al. studied homogenous 
myelopathy patients with monosegemental chronic degenerative stenosis using 18FDG-PET, 
and found that patients with chronic compressive myelopathy had normal glucose 
utilization just above the level of the stenosis but significantly decreased 18FDG uptake 
below the level of cord compression (Floeth, Stoffels et al.2010). They noted that these 
results are compatible with those of Baba et al. (Baba, Uchida et al. 1999).  
 
 
Fig. 5. MRI (a) and PET (b) showing homogenous FDG uptake in a patient with a normal 
cord, and MRI (c) and PET (d) illustrating reduced FDG uptake at the compression level in a 
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18FDG-PET can reflect the glucose utilization of the spinal cord in spinal disorder patients 
(Figure 5). It can be an important predictor for prognosis and neurological improvement 
after neurosurgical decompression. However, 18FDG uptake is affected by the range of 
stenosis, whether it is bi- or multisegmental stenosis, and duration and severity of 
symptoms. Further studies in a larger series of patients with chronic and clinically stable 
myelopathy, and in patients with an acute and rapidly progressing myelopathy are 
needed. 
5. Conclusion 
18FDG-PET is important not only for detecting malignant tumors but also for its potential 
use in the evaluation of a variety of inflammatory and infectious disorders (Zhuang, Yu et 
al. 2005). For oncology, there is the limitation that 18FDG-PET cannot differentiate between 
malignant and inflammatory processes. However, this limitation would be considered an 
advantage when screening for spinal anomalies and benign neurogenic tumors. Therefore, 
despite the high cost and relative scarcity of PET scanners at institutions, the role of PET in 
screening for and assessment of benign neurogenic tumors and compressive myelopathies is 
expected to increase. 
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